Association of gut microbiota with the pathogenesis of SARS-CoV-2 Infection in people living with HIV

Ishizaka, Aya; Koga, Michiko; Mizutani, Taketoshi; Yamayoshi, Seiya; Iwatsuki-Horimoto, Kiyoko; Adachi, Eisuke; Suzuki, Yutaka; Kawaoka, Yoshihiro; Yotsuyanagi, Hiroshi

doi:10.1186/s12866-023-03157-5

BMC Microbiology

Table 1 General characteristics of COVID-19 patients and their clinical presentation in HIV treatment

From: Association of gut microbiota with the pathogenesis of SARS-CoV-2 Infection in people living with HIV

Patient ID	Variant	Age	Severity	Stool collection days from COVID-19 onset				COVID-19 treatment						PACS	ART regimen	Comorbidities	Vaccination times before SARS-CoV-2 infection
Patient ID	Variant	Age	Severity	d1-7	d8-14	d30 ~		Steroid use	Antibiotics use	medication used 1	medication used 2	medication used 3	PPI	symptoms	ART regimen	Comorbidities	Vaccination times before SARS-CoV-2 infection
1	α	51	mild	d6				No	No	day10-14			No	No	TAF/FTC/BIC	HIV, dyslipidemia, depression	No
1	α	51	mild	d6				No	No	Lopinavir, ritonavir			No	No	TAF/FTC/BIC	HIV, dyslipidemia, depression	No
2	α	27	moderate	d3	d10			No	No	day1-5			No	No	TAF/FTC/BIC	HIV, syphilis, asthma	No
2	α	27	moderate	d3	d10			No	No	Favipiravir			No	No	TAF/FTC/BIC	HIV, syphilis, asthma	No
3	α	54	severe		d10			Yes	Yes	day7-11	day6-7	day7-12	day6-	No	ABC/3TC/DTG	HIV, diabetes, high blood pressure, dyslipidemia, hyperuricemia, cerebral infarction	No
3	α	54	severe		d10			Yes	Yes	Remdesivir	Dexamethasone	methylprednisolone	Rabeprazole Sodium	No	ABC/3TC/DTG		No
4	α	42	mild	d5	d10	d53		No	No	No			No	No	TAF/FTC/DTG	HIV	No
5	α	26	mild	d2	d9			No	No	No			No	No	TAF/FTC/BIC	HIV	No
6	α	51	moderate	d5	d11	d82		No	No	No			No	No	TAF/FTC/BIC	HIV, atopic dermatitis, uveitis, asthma, dyslipidemia, obesity	No
7	α	53	moderate	d5	d8	d48		No	No	No			No	No	TAF/FTC/RPV	HIV, asthma, high blood pressure	No
8	α	46	mild	d2	d11	d67	d382	No	No	day3-7			No	Yes	CABLA + RPVLA	HIV	No
8	α	46	mild	d2	d11	d67	d382	No	No	Remdesivir			No	hair loss	CABLA + RPVLA	HIV	No
9	α	42	mild	d4	d13	d44		Yes	No	day9-13			day9-18	No	3TC/DTG	HIV, Herpes zoster	No
9	α	42	mild	d4	d13	d44		Yes	No	Dexamethasone			Esomeprazole Magnesium Hydrate	No	3TC/DTG	HIV, Herpes zoster	No
10	delta	60	moderate		d9			Yes	No	day8-12	day8-13		day8-13	No	TAF/FTC/BIC	HIV	No
10	delta	60	moderate		d9			Yes	No	Remdesivir	Dexamethasone		Esomeprazole Magnesium Hydrate	No	TAF/FTC/BIC	HIV	No
11	BA.1	54	mild	d4	d11	d31	d128	No	No	day3-7			No	Yes	ABC/3TC/DTG	HIV, sinusitis, allergic rhinitis, knee osteoarthritis, fatty liver	1 (mRNA-1273)
11	BA.1	54	mild	d4	d11	d31	d128	No	No	Molnupiravir			No	Fatigue, brain fog	ABC/3TC/DTG		1 (mRNA-1273)
12	BA.2	54	mild	d4	d9	d85		No	No	day2			No	No	3TC/DTG	HI, Kaposi's sarcom, lacunar infarction, fatty liver, renal cyst	2 (BNT162b)
12	BA.2	54	mild	d4	d9	d85		No	No	Sotrovimab			No	No	3TC/DTG		2 (BNT162b)

Back to article page

ISSN: 1471-2180

Contact us

General enquiries: journalsubmissions@springernature.com